Stockreport

Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration

IMMUNOMEDICS  (IMMU) 
Last immunomedics earnings: 2/27 04:00 pm Check Earnings Report
PDF MORRIS PLAINS, N.J., May 21, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a science-based and innovation-focused bioph [Read more]